Beginning with FDA news, the administration Xenon Pharmaceuticals has submitted a new drug application (NDA) to the FDA for ...
In recognition of International Ataxia Awareness Day, observed annually on NeurologyLive® reviews 6 investigational agents ...
Exploring the Link Between Football Players and ALS: Brian Lin, PhD In a recent Q&A interview, Brian Lin, PhD, research ...
Neurology moves fast, and the assumptions that shape how we practice do not always keep up. Gray Areas is a NeurologyLive ...
In this episode, host Lindsay Ross, MD, is joined by joined by Rachel Galioto, PhD, a Cleveland Clinic neuropsychologist ...
Results recently published from the phase 2 HIMALAYA trial reported that SAR443820 did not slow functional decline, and was associated with more adverse events and treatment discontinuations in ...
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
Twelve observational studies (1997–2025) demonstrated a bidirectional migraine–colic association, including both maternal ...
Thirty-day headache history dominated feature importance; rolling mean severity alone contributed 37.6% and 30-day window features 56.3%, versus 11.1% for prodromal symptom features. Forecast ...
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results